Results 11 to 20 of about 78,528 (234)

Editorial: Host-Directed Therapies for Tuberculosis [PDF]

Frontiers in Cellular and Infection Microbiology, 2021
Diego L. Costa, Diego L. Costa, Mamoudou Maiga, Mamoudou Maiga, Selvakumar Subbian   +4 more
doaj   +5 more sources

Granulomas and inflammation: Host-Directed Therapies for Tuberculosis [PDF]

Frontiers in Immunology, 2016
Tuberculosis remains a leading global health problem that is aggravated by emergence of drug-resistant strains, which account for increasing number of treatment-refractory cases.
Hlumani Ndlovu, Mohlopheni J Marakalala
doaj   +6 more sources

Host-directed therapies for tuberculous pericarditis [PDF]

International Journal of Infectious Diseases, 2015
TB Pericarditis is associated with significant inflammatory and immune responses which can paradoxically cause injury to the pericardium and myocardium. Management with anti-TB therapy alone does not prevent complications or reduce mortality.
Alimuddin Zumla, Markus Maeurer, Guido Moll, Bongani M. Mayosi   +3 more
doaj   +3 more sources

Targeting Molecular Inflammatory Pathways in Granuloma as Host-Directed Therapies for Tuberculosis [PDF]

Frontiers in Immunology, 2021
Globally, more than 10 million people developed active tuberculosis (TB), with 1.4 million deaths in 2020. In addition, the emergence of drug-resistant strains in many regions of the world threatens national TB control programs.
Reto Guler, Reto Guler, Reto Guler, Mumin Ozturk, Mumin Ozturk, Solima Sabeel, Solima Sabeel, Bongani Motaung, Bongani Motaung, Suraj P. Parihar, Suraj P. Parihar, Suraj P. Parihar, Friedrich Thienemann, Friedrich Thienemann, Friedrich Thienemann, Frank Brombacher, Frank Brombacher, Frank Brombacher   +17 more
doaj   +2 more sources

Towards host-directed therapies for tuberculosis [PDF]

Nature Reviews Drug Discovery, 2015
The treatment of tuberculosis is based on combinations of drugs that directly target Mycobacterium tuberculosis. A new global initiative is now focusing on a complementary approach of developing adjunct host-directed therapies.
Zumla, A., Chakaya, J., Hoelscher, M., Ntoumi, F., Rustomjee, R., Vilaplana, C., Yeboah-Manu, D., Rasolof, V., Munderi, P., Singh, N., Aklillu, E., Padayatchi, N., Macete, E., Kapata, N., Mulenga, M., Kibiki, G., Mfinanga, S., Nyirenda, T., Maboko, L., Garcia-Basteiro, A., Rakotosamimanana, N., Bates, M., Mwaba, P., Reither, K., Gagneux, S., Edwards, S., Mfinanga, E., Abdulla, S., Cardona, P. J., Russell, J. B., Gant, V., Noursadeghi, M., Elkington, P., Bonnet, M., Menendez, C., Dieye, T. N., Diarra, B., Maiga, A., Aseffa, A., Parida, S., Wejse, C., Petersen, E., Kaleebu, P., Oliver, M., Craig, G., Corrah, T., Tientcheu, L., Antonio, M., Rao, M., McHugh, T. D., Sheikh, A., Ippolito, G., Ramjee, G., Kaufmann, S. H., Churchyard, G., Steyn, A., Grobusch, M., Sanne, I., Martinson, N., Madansein, R., Wilkinson, R. J., Mayosi, B., Schito, M., Wallis, R. S., Maeurer, M.   +64 more
openaire   +7 more sources

Immunometabolic Signature during Respiratory Viral Infection: A Potential Target for Host-Directed Therapies [PDF]

Viruses, 2023
RNA viruses are known to induce a wide variety of respiratory tract illnesses, from simple colds to the latest coronavirus pandemic, causing effects on public health and the economy worldwide.
Larissa Menezes dos Reis, Marcelo Rodrigues Berçot, Bianca Gazieri Castelucci, Ana Julia Estumano Martins, Gisele Castro, Pedro M. Moraes-Vieira   +5 more
doaj   +2 more sources

Host-directed therapies for multidrug resistant tuberculosis

International Journal of Mycobacteriology, 2016
Tuberculosis (TB) causes 1.3 million deaths annually. There are 0.5 million cases of multidrug resistant TB (MDR-TB) and the number of cases is rising globally.
Alimuddin Zumla, Markus Maeurer
doaj   +4 more sources

Mitigating the Impact of Antibacterial Drug Resistance through Host-Directed Therapies: Current Progress, Outlook, and Challenges [PDF]

mBio, 2018
Increasing incidences of multidrug resistance in pathogenic bacteria threaten our ability to treat and manage bacterial infection. The development and FDA approval of novel antibiotics have slowed over the past decade; therefore, the adoption and ...
Chih-Yuan Chiang, Ijeoma Uzoma, Richard T. Moore, Merle Gilbert, Allen J. Duplantier, Rekha G. Panchal   +5 more
doaj   +2 more sources

Identification of kinase inhibitors as potential host-directed therapies for intracellular bacteria [PDF]

Scientific Reports
The emergence of antimicrobial resistance has created an urgent need for alternative treatments against bacterial pathogens. Here, we investigated kinase inhibitors as potential host-directed therapies (HDTs) against intracellular bacteria, specifically ...
Robin H. G. A. van den Biggelaar, Kimberley V. Walburg, Susan J. F. van den Eeden, Cassandra L. R. van Doorn, Eugenia Meiler, Alex S. de Ries, M. Chiara Fusco, Annemarie H. Meijer, Tom H. M. Ottenhoff, Anno Saris   +9 more
doaj   +2 more sources

Host-Directed Antiviral Therapy [PDF]

Clinical Microbiology Reviews, 2020
Antiviral drugs have traditionally been developed by directly targeting essential viral components. However, this strategy often fails due to the rapid generation of drug-resistant viruses. Recent genome-wide approaches, such as those employing small interfering RNA (siRNA) or clustered regularly interspaced short palindromic repeats (CRISPR) or those ...
Naveen Kumar, Shalini Sharma, Ram Kumar, Bhupendra N. Tripathi, Sanjay Barua, Hinh Ly, Barry T. Rouse   +6 more
openaire   +2 more sources